Form 4: AnaptysBio Director Dennis Fenton Acquires Shares Through RSU Vesting

AnaptysBio, Inc. Director Dennis M. Fenton acquired 6,030 shares of common stock through the vesting of restricted stock units on June 15, 2025, increasing his direct beneficial ownership to 7,980 shares.

Summary

• Dennis M. Fenton, a Director of AnaptysBio, Inc. (ANAB), acquired 6,030 shares of common stock.
• This acquisition resulted from the vesting and settlement of Restricted Stock Units (RSUs).
• The transaction occurred on June 15, 2025.
• The shares were acquired at a price of $0, as is typical for RSU settlements.
• Following this transaction, Mr. Fenton directly beneficially owns 7,980 shares of AnaptysBio common stock.
• The 6,030 Restricted Stock Units were disposed of as they converted into common stock, leaving 0 derivative securities of this type.
• The RSUs vested 100% on the date of the Issuer's 2025 annual meeting of shareholders, contingent on Mr. Fenton's continued service.

Sentiment

Score: 7

Explanation: The filing reports a routine, expected insider transaction (RSU vesting) which is generally positive as it aligns director interests with shareholders and indicates continued service. There are no negative implications.

Positives

• Director Dennis M. Fenton increased his direct beneficial ownership in AnaptysBio, Inc. by 6,030 shares, indicating continued alignment with shareholder interests.
• The vesting of Restricted Stock Units (RSUs) suggests the fulfillment of service-based compensation criteria.

Future Outlook

The filing indicates that the Restricted Stock Units vested on the date of the Issuer's 2025 annual meeting of shareholders, contingent on the reporting person's continued service, implying a future event for the vesting condition.

Industry Context

This Form 4 filing reports an insider transaction, specifically the vesting of equity compensation for a director. Such transactions are common in the biotechnology and pharmaceutical industries, where equity-based compensation is a standard practice to align management and director incentives with long-term shareholder value. It does not provide broader industry trends or competitive analysis.

Comparison to Industry Standards

• This filing reports a standard equity compensation event (RSU vesting) for a director, which is a common practice across publicly traded companies, including those in the biotechnology sector like AnaptysBio. There are no specific comparable companies, projects, or results mentioned in this Form 4 to allow for a detailed comparative assessment beyond the general observation that equity compensation is a standard industry practice.

Stakeholder Impact

• Shareholders: Increased direct ownership by a director can be seen as a positive signal of alignment with shareholder interests.
• Employees: The RSU vesting is part of a compensation structure, which is a standard practice for attracting and retaining talent, including directors.

Next Steps

• Continued service of Dennis M. Fenton to AnaptysBio, Inc. to fulfill vesting conditions for future equity awards, if any.
• Future Form 4 filings for any subsequent insider transactions by Dennis M. Fenton.

Key Dates

Keywords

AnaptysBio, ANAB, Form 4, Insider Transaction, Restricted Stock Units, RSU Vesting, Director Stock Acquisition, Dennis M. Fenton, Equity Compensation